Jafron Biomedical: 2021H1 net profit about 620 million yuan, an increase of 40.74% YoY
NBD AI Bulletin -- Jafron Biomedical Co., Ltd (SZ 300529, close price: 68.95 yuan) released on August 2 the semi-annual results, saying that in the first half of 2021, the Company recorded revenue of around 1.188 billion yuan, the net profit attributable to shareholders amounted to around 620 million yuan, up 40.74% year on year, and the basic earnings per share was 0.78 yuan.
The 2020 annual report shows that the main business of Jafron Biomedical Co Ltd is the medical device manufacturing industry and other, accounting for 99.57%, 0.2% of revenue, respectively.
Jafron Biomedical's chairman and general manager is Dong Fan, male, 51 years old, Chinese national, no overseas permanent residency, master's degree.
(By Gao Han)
Disclaimer: The content and data of this article are for reference only and do not constitute investment advice. Please verify before use. Any action you take upon the information on this website is at your own risk.